Longeveron (LGVN) Non-Current Deferred Tax Liability (2022 - 2023)
Longeveron's (LGVN) quarterly Non-Current Deferred Tax Liability came in at $391000.0 in Q4 2023, down 3.69% year-on-year from $406000.0 in Q4 2022, and down 3.69% quarter-over-quarter from $406000.0 in Q4 2022.
Longeveron (LGVN) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Longeveron's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $391000.0 for Q4 2023.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 3.69% year-over-year to $391000.0 in Q4 2023; TTM through Dec 2023 was $391000.0, a 3.69% decrease from a year earlier, with the FY2023 full-year figure at $391000.0, down 3.69% from the prior year.
- Non-Current Deferred Tax Liability fell to $391000.0 in Q4 2023 per LGVN's latest filing, from $406000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $406000.0 in Q4 2022 and bottomed at $391000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 391,000.00 |
| Dec 31, 2023 | 391,000.00 |
| Dec 31, 2022 | 406,000.00 |
| Dec 31, 2022 | 406,000.00 |